JBC PeproTech; Our Business is Cytokines!

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.C200086200 on March 7, 2002

J. Biol. Chem., Vol. 277, Issue 17, 14351-14354, April 26, 2002
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/17/14351    most recent
C200086200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ogawa, A.
Right arrow Articles by Tsukihara, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ogawa, A.
Right arrow Articles by Tsukihara, T.

ACCELERATED PUBLICATION
Structure of the Carboxyl-terminal Src Kinase, Csk*

Akira OgawaDagger , Yoshiharu TakayamaDagger §, Hiroaki SakaiDagger , Khoon Tee ChongDagger , Satoru TakeuchiDagger , Atsushi NakagawaDagger , Shigeyuki Nada||, Masato Okada||, and Tomitake TsukiharaDagger

From the Dagger  Institute for Protein Research, Osaka University, 3-2 Yamadaoka and || Research Institute for Microbial Diseases, Osaka University, 3-1 Yamadaoka, Suita, Osaka 565-0871, Japan

Received for publication, February 12, 2002, and in revised form, March 3, 2002

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

The carboxyl-terminal Src kinase (Csk) is an indispensable negative regulator for the Src family tyrosine kinases (SFKs) that play pivotal roles in various cell signalings. To understand the molecular basis of the Csk-mediated regulation of SFKs, we elucidated the crystal structure of full-length Csk. The Csk crystal consists of six molecules classified as active or inactive states according to the coordinations of catalytic residues. Csk assembles the SH2 and SH3 domains differently from inactive SFKs, and their binding pockets are oriented outward enabling the intermolecular interaction. In active molecules, the SH2-kinase and SH2-SH3 linkers are tightly stuck to the N-lobe of the kinase domain to stabilize the active conformation, and there is a direct linkage between the SH2 and the kinase domains. In inactive molecules, the SH2 domains are rotated destroying the linkage to the kinase domain. Cross-correlation matrices for the active molecules reveal that the SH2 domain and the N-lobe of the kinase domain move as a unit. These observations suggest that Csk can be regulated through coupling of the SH2 and kinase domains and that Csk provides a novel built-in activation mechanism for cytoplasmic tyrosine kinases.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

The Src family tyrosine kinases (SFKs),1 benign relatives of the oncogenic v-src gene product, are non-receptor types of protein tyrosine kinases (PTKs) that are associated with the plasma membrane through their fatty acylated N termini (1). The SFKs serve as molecular switches involved in the initiation of a variety of cellular events in the multicellular animals, including cell growth and division, cell attachment and movement, differentiation, survival, and death (2). The SFKs are ordinarily present in an inactive state in which the phosphorylated C-terminal regulatory tyrosine binds to its own SH2 domain (3). In response to an external stimulus, an SFK becomes activated through dephosphorylation of the C-terminal tyrosine or through binding to another protein that displaces the intramolecular interaction. The phosphorylation of the regulatory tyrosine of SFK is strictly controlled by another PTK, the C-terminal Src kinase (Csk) (4, 5). The loss-of-function of Csk leads to constitutive activation of SFKs, accompanied by severe defects in embryonic development (5). In contrast, gain-of-function of Csk can readily down-regulate SFK-mediated cell signaling (6). Therefore, to understand the function and regulation of SFKs, it is essential to clarify the regulation mechanism controlling the phosphorylation of the critical C-terminal tyrosine.

Csk is a cytoplasmic PTK consisting of an SH3, an SH2, and a kinase domain (4). Because it lacks an N-terminal acylation signal, an autophosphorylation site, and a C-terminal regulatory tyrosine, all of which are conserved among SFKs, the regulatory mechanism of Csk appears to be quite different from those of SFKs. The molecular basis of Csk regulation has so far been studied using mutated molecules and isolated domains (7, 8). However, lack of the entire structure of Csk has hampered the evaluation of their physiological roles. Some evidence suggests that the SH2 and/or SH3 domain of Csk is essential for SFK regulation (7, 9) and that recruitment to the membrane is required for Csk function (6, 10). In this context, we and others have recently identified a membrane phosphoprotein that can tightly bind to the SH2 domain of Csk (Cbp or PAG) (11, 12). Upon phosphorylation, Cbp/PAG can recruit Csk to a membrane microdomain, so-called lipid Rafts, to terminate SFK signaling. More recently, we found that the binding to the phosphorylated Cbp/PAG could directly activate Csk (13). Thus it is likely that Cbp/PAG plays an important role in Csk regulation. On the other hand, other proteins that could functionally bind to the SH2 domain of Csk, such as Paxillin and FAK, have been identified previously (7). These findings suggest that Csk is regulated through its SH2 domain in vivo, although the molecular basis of this regulation remains thoroughly unknown. To address this issue, we here elucidated the entire structure of Csk by crystallographic analysis.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

Expression and Purification of Csk-- The full-length (amino acids 1-450) rat Csk was expressed using baculovirus vector in insect cells and purified essentially by the same methods as described previously (13), except that beta -octyl-D-glucoside was added (instead of Nonidet P-40) to the buffer during chromatography processes and that the final gel filtration chromatography was performed in a buffer consisting of 100 mM Tris-HCl (pH 8.5), 150 mM NaCl, 5 mM beta -mercaptoethanol, 1 mM EDTA, 5% glycerol, and 0.02% beta -octyl-D-glucoside. Size estimation was carried out on a Superdex200 HR10/30 column equilibrated with phosphate-buffered saline. Sedimentation equilibrium was performed by ultracentrifugation at 17,000 rpm for 22 h. Concentration distributions were measured using the Rayleigh interference optics.

Crystal Structure Analysis-- The purified Csk was concentrated to ~12 mg/ml, mixed with 50 mM Hepes-NaOH (pH 7.4) containing 1.90-1.95 M ammonium sulfate, and crystallized in a sitting drop by vapor diffusion at 288 K for 1-2 months. All data were collected at the cryogenic temperature (around 100 K) using 25% (v/v) ethylene glycol as a cryoprotectant. The native1, native2, and Hg data were collected on the PX210 (Oxford) at BL44XU, Quantum4 (adsc) at BL40B2, and on the marCCD (Mar research) at BL41XU in SPring-8, respectively. The diffraction images were reduced and scaled with Mosflm (ccp4 (14)) and Scala (ccp4) in native1 and Denzo/Scalepack (15) in native2 and Hg data sets. The intensities were converted to the structure factor amplitudes with TRUNCATE (ccp4). Subsequent phasing calculations were performed using native2 and Hg data. The six Hg positions were first located using SHELXS-97 (16), followed by the minor site specification, heavy atom parameter refinement, and the SIRAS phase calculation with SHARP (17). The density modification with SOLOMON (ccp4) permitted us clear interpretation of the electron density map. The atomic model was built using O (18) and refined with the native1 data set using CNS (19). Of the 2,298 non-glycine and non-proline residues, 83.0% fell into the most favored regions, 16.1% into the additional allowed regions, 0.9% into the generously allowed regions, and no residue into the disallowed regions of Ramachandran plot as defined in PROCHECK. Coordinates have been deposited with the Protein Data Bank under accession codes 1K9A.

    RESULTS AND DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

Overview of Csk Structure-- The full-length rat Csk was produced using a baculovirus vector in insect cells and purified through sequential column chromatography. Although Csk from the brain tissue (<0.01 mg/ml) behaved as a monomer (50 kDa) on gel filtration chromatography (20), the highly concentrated Csk from insect cells (>1 mg/ml) was eluted with an apparent molecular size around 100 kDa (data not shown). Sedimentation equilibrium analysis also revealed that Csk is present as a dimer at concentrations around 1 mg/ml (data not shown). These findings demonstrate that Csk tends to dimerize at high protein concentrations in vitro. The crystal structure of Csk was solved by the heavy atom single isomorphous replacement method. Crystallographic data and refinement statistics are shown in Table I. An interesting feature of Csk crystal is that it consists of six molecules divided into three pairs of putative dimers per asymmetric unit. This is probably because of oligomerization of Csk dimers during crystallization processes. The dimers are made with loose interactions through the backside of the kinase domains and the SH3 domains. Two of the six molecules, in distinct dimers, make further contact with each other and appear to have some distortions in their structures as described later. In every molecule, however, the three functional domains, SH2, SH3, and kinase, are arranged in a similar manner with the SH2 and SH3 domains diametrically opposite on the top of the N-lobe of the kinase domain (Fig. 1, A and C). Although the position of the SH3 domain resembles the position of the SH3 domain of inactive forms of SFKs, the position of the SH2 domain is entirely different (3). In addition, there is no direct contact between the SH2 and SH3 domains of Csk.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Summery of crystallographic data and refinement statistics


View larger version (38K):
[in this window]
[in a new window]
 
Fig. 1.   A, ribbon diagram of a representative Csk structure (active molecule) in the crystal. Domain structures are distinctively colored: SH2 in blue, SH3 in purple, N-lobe in dark green, C-lobe in light green, and the activation segment in red. B, superimposed model of the six Csk molecules in an asymmetric unit. Active molecules are shown in green and inactive molecules are in blue. C, schematic models of the structures of Csk (left) and c-Src (right). Peptide binding pockets of the SH2 and SH3 domains are shown by hollows. The rotated SH2 domain of the inactive molecule is colored pink. Phosphate on the tail tyrosine (Tyr-527) of c-Src is colored red.

Arrangements of the SH2 and SH3 Domains-- The SH3 domains fold canonically with two anti-parallel sheets of five beta -strands sandwiched into a compact structure. There are virtually no differences from the structure of an isolated Csk-SH3 domain (21) except that the N-terminal region is disordered in the isolated SH3 domain (Fig. 1A). The peptide-binding pocket of the SH3 domain is oriented outward (Fig. 1C) enabling the intermolecular interaction, and the interactions between the SH3 and SH2-kinase linker observed in inactive SFK structures are absent. The SH2 domains are also canonical, consisting of a central beta -sheet flanked by two alpha -helices as in c-Src (Fig. 1A), although an insertion is present in the loop region of the c-Src SH2 domain. However, a significant difference can be observed in the orientations of the SH2 domains when all six Csk molecules are superimposed (Fig. 1B). In four Csk molecules, the ligand binding surfaces face to the left in Fig. 1B, whereas those of the other two are rotated upward ~60° (Fig. 1B). This disorientation may reflect an unusual flexibility of the SH3-SH2 linker and SH2-kinase linker, which form a hinge about which the SH2 domain pivots. These two linkers make extensive hydrophobic contacts with the N-lobe of the kinase domain (Fig. 1A and Fig. 3). In the SH2-kinase linker, there is an alpha -helix, which is designated as alpha BC, that is absent from SFKs (Fig. 1A). All the hydrophobic residues involved in engaging the SH2 and kinase domains are highly conserved among Csks derived from various species, suggesting that docking of the SH2 linkers into the kinase domain is important for regulation.

Active Conformation of the Kinase Domain-- The kinase domains of the four Csk molecules whose SH2 domains face to the left in Fig. 1B can be readily superimposed on the kinase domain of an active SFK, Lck (22). The positions of residues crucial for catalytic activity (Asp-314, Asn-319, and Asp-332) and the critical ion bridge that orients the gamma -phosphate of ATP (Glu-236 in alpha C and Lys-222 in beta 3) are consistent with those of Lck (Fig. 2, A and B). All these features suggest that the four molecules are most likely to be enzymatically active. The active site similarity with Lck is rather remarkable considering that Csk differs from SFKs in its activation loop (Fig. 2, red). The activation loop of Csk (331-348) is four residues shorter than and diverged from that of Lck, and, critically, it lacks a phosphorylated tyrosine residue (Fig. 2E). In addition, Csk residues are either substantially displaced as compared with their counterparts in Lck (338-342, 346-349) or disordered (343-345). In SFKs, autophosphorylation of the activation loop tyrosine is regulatory and essential for full catalytic activity and for transforming potential (23, 24). In Lck, this phosphotyrosine (Tyr-394) is essential to coordinate Arg-363 and Arg-387 and thus stabilize the active structure. In Csk, however, the side chain of Lys-337, which corresponds to Arg-387 in Lck, has no apparent coordinations to a specific partner, yet the main chain lies within 1.5 Å of Lck Arg-337 when the C-lobes are superimposed.


View larger version (43K):
[in this window]
[in a new window]
 
Fig. 2.   Arrangements of the catalytically important residues in Lck (A), active Csk and a simulated annealing omit map at 1.5 sigma  in the vicinity of the salt bridge between Lys-222 and Glu-236 (B), inactive Csk (C), and the isolated kinase domain of Csk (27) (D) are shown. The salt bridge between Lys-222 and Glu-236 is indicated by dotted line in A and B. E, sequence alignment of the activation loops of Csk, Lck, c-Src (Src) and insulin receptor kinase (IRK). Autophosphorylated tyrosines are colored red.

The similarity in active sites despite the absence of phosphate in the activation loop suggests that another mechanism maintains the active conformation of Csk. Previously it has been reported that deletion of sequences preceding the kinase domain significantly reduces Csk activity (7, 8, 25, 26), and a role of the SH3-SH2 linker in Csk activation has been suggested (8). In a structure of the isolated kinase domain bound to staurosporine, the helix alpha C is kinked and flexible, destroying the critical salt bridge between Lys-222 and Glu-236 (Fig. 2D) (27). In the case of Lck, however, an isolated kinase domain retains full activity (28). As already mentioned, in Csk there are tight interactions between the two linkers and the N-lobe of the kinase domain. Notably, the helix alpha C, which positions Glu-236, is oriented by extensive contacts with the linkers (Fig. 3). This resembles the case of CDK2 that is partially activated through binding to cyclin A (29). The binding of cyclin A to the helix alpha C (containing PSTAIRE motif) of CDK2 induces a dramatic change in the orientation of the helix alpha C so that the catalytic residues are appropriately coordinated for the catalysis. Therefore, instead of the activating phosphotyrosine, Csk may require the interaction between the kinase domain and the linkers to stabilize the active conformation.


View larger version (33K):
[in this window]
[in a new window]
 
Fig. 3.   Stereo representations of the interaction between the SH3-SH2 linker, SH2-kinase linker, and the kinase domain in active Csk (A) and inactive Csk (B). The interaction between the beta D-beta E loop and beta 3-alpha C loop cannot been seen in the inactive Csk.

Inactive Conformation of the Kinase Domain-- In contrast with the active molecules, the two Csk molecules with rotated SH2 domains appear to be inactive. These molecules are substantially different from the active molecules in the backbone carbon positions of the N-lobe of the kinase domain (Fig. 1B). Importantly, the critical ion pair (between Glu-236 and Lys-222) is absent (Fig. 2C) although the conformation of the catalytic domain is apparently different from that of the isolated kinase domain bound to staurosporine (27). Furthermore, there is a major difference between the active and inactive molecules in the SH2-kinase interface (Fig. 3); the interactions between the beta D-beta E loop of the SH2 domain and beta 3-alpha C loop in the N-lobe of kinase domain are absent in the inactive molecules. These indicate that rotation of the SH2 domain could affect the conformation of the N-lobe of the kinase domain, implicating the functional relationship between the SH2 domain and the kinase domain.

Regulatory Feature of Csk-- To address the above issue, we calculated cross-correlation matrices for the deviations of the backbone carbon atoms of the molecules in the crystal. The cross-correlation matrix was recently found to be useful to assess interdomain interactions in molecular dynamics studies (30). Fortunately, our crystal contained multiple copies of Csk molecules in an asymmetric unit, and we used four crystallographically independent copies instead of conformational snapshots in the molecular dynamics study. The C-lobes of the kinase domains were first superimposed by the program LSQKAB (14), and then we generated a set of averaged positions of the alpha  carbon. The correlation between two atoms can be defined using the deviations from their respective average positions. It is obvious that the correlation value for two atoms in the same domain shows an absolute value close to 1 as the domain moves en bloc. If two residues move independently, the correlation will be near 0. It is usually observed that the correlation between two atoms in the "superimposed" region is flattened to 0. As shown in Fig. 4, for four active-state molecules, clusters of positive correlations between two atoms lie in the regions indicating correlations between the SH2 domain and beta 1-beta 2 and beta 3-alpha C regions of the kinase domain. This indicates that these segments deviate en bloc in the crystal, representing a functional coupling between the SH2 and the kinase domain.


View larger version (127K):
[in this window]
[in a new window]
 
Fig. 4.   Cross-correlation matrices for the four active Csk molecules. The SH2 domain (82-172), beta 1-beta 2 and beta 3-alpha C loop (204-207), and beta 3-alpha C loop and alpha C (225-243) are emphasized by the bold lines. The C-lobes of four molecules were superimposed prior to the calculation. The correlation coefficients cij, which are plotted according to the scale indicated on the top, are defined as cij = Sigma (ri·rj)/((Sigma |ri|2)1/2(Sigma |rj|2)1/2), where ri is the deviation of the backbone carbon position from the average position of the "i"th residue.

The structure of Csk presented here highlights the functional interactions of the catalytic domain with the SH2 domain and its linkers and suggests a novel activation mechanism that is distinct from the phosphorylation-dependent regulation of SFKs. The presence of an inactive conformation of Csk, which is probably produced by the unusual flexibility of the hinge region of the SH2 domain, also suggests that there may be a dynamic equilibrium between active and inactive Csk. It is known that a strong ligand of the SH2 domain, the phosphorylated Cbp/PAG, could elicit potentially full activity of Csk (13). Therefore, it is probable that binding of Cbp/PAG ligand to the SH2 domain could fix the active state to make the kinase constitutively active. It is also possible that the conformation change induced by the SH2 ligand could affect the region responsible for the substrate recognition. To verify these hypotheses, the structural details of Csk association with Cbp/PAG are now under investigation.

Among the many types of cytoplasmic protein tyrosine kinases, including the Fes, Abl, Syk, Tec, and Csk families, the SFKs are unusual in that they are negatively regulated by phosphorylation of the C-terminal regulatory site. The SH2 domain of the SFK serves as an acceptor for the phosphorylated regulatory tyrosine. All the aforementioned cytoplasmic tyrosine kinases also possess an SH2 domain adjacent to the catalytic domain but have no C-terminal phosphotyrosine. Although the actual roles of SH2 domains in these enzymes remain to be studied at the molecular level, the structures of Csk presented here could be representative of cytoplasmic tyrosine kinases other than SFKs.

    ACKNOWLEDGEMENTS

We thank J. A. Cooper for discussions and comments on the manuscript, T. Hirose and A. Nagata for production of recombinant Csk in Sf9 cells, N. Ito for aid in matrix presentation, K. Yutani and M. Sakai for sedimentation equilibrium analysis, E. Yamashita for valuable technical comments and suggestions, and beamline staffs at SPring-8 including M. Kawamoto and K. Miura for help in data collection.

    FOOTNOTES

* This work was supported in part by grants-in-aid from the Ministry of Education, Science, Sports and Culture of Japan and by grants from The Nagase Science and Technology Foundation, The Mitsubishi Foundation, Japan Research Foundation for Clinical Pharmacology, and The Program for Promotion of Fundamental Studies in Health Sciences of the Organization for Pharmaceutical Safety and Research.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The atomic coordinates and the structure factors (code 1K9A) have been deposited in the Protein Data Bank, Research Collaboratory for Structural Bioinformatics, Rutgers University, New Brunswick, NJ (http://www.rcsb.org/).

§ Present address: National Institute of Livestock and Grassland Science 2, Ikenodai, Kukizaki, Inashiki, Ibaraki 305-0901, Japan.

To whom correspondence may be addressed. E-mail: okadam@ biken.osaka-u.ac.jp or atsushi@protein.osaka-u.ac.jp.

Published, JBC Papers in Press, March 7, 2002, DOI 10.1074/jbc.C200086200

    ABBREVIATIONS

The abbreviations used are: SFK, Src family tyrosine kinase; PTK, protein tyrosine kinase.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

1. Brown, M. T., and Cooper, J. A. (1996) Biochim. Biophys. Acta 1287, 121-149[Medline] [Order article via Infotrieve]
2. Thomas, S. M., and Brugge, J. S. (1997) Annu. Rev. Cell Dev. Biol. 13, 513-609[CrossRef][Medline] [Order article via Infotrieve]
3. Xu, W., Harrison, S. C., and Eck, M. J. (1997) Nature 385, 595-602[CrossRef][Medline] [Order article via Infotrieve]
4. Nada, S., Okada, M., MacAuley, A., Cooper, J. A., and Nakagawa, H. (1991) Nature 351, 69-72[CrossRef][Medline] [Order article via Infotrieve]
5. Nada, S., Yagi, T., Takeda, H., Tokunaga, T., Nakagawa, H., Ikawa, Y., Okada, M., and Aizawa, S. (1993) Cell 73, 1125-1135[CrossRef][Medline] [Order article via Infotrieve]
6. Chow, L. M., Fournel, M., Davidson, D., and Veillette, A. (1993) Nature 365, 156-160[CrossRef][Medline] [Order article via Infotrieve]
7. Sabe, H., Hata, A., Okada, M., Nakagawa, H., and Hanafusa, H. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 3984-3988[Abstract/Free Full Text]
8. Shekhtman, A., Ghose, R., Wang, D., Cole, P. A., and Cowburn, D. (2001) J. Mol. Biol. 314, 129-138[CrossRef][Medline] [Order article via Infotrieve]
9. Cloutier, J. F., Chow, J. M., and Veillette, A. (1995) Mol. Cell. Biol. 15, 5937-5944[Abstract]
10. Howell, B. W., and Cooper, J. A. (1994) Mol. Cell. Biol. 14, 5402-5411[Abstract/Free Full Text]
11. Kawabuchi, M., Satomi, Y., Takao, T., Shimonishi, Y., Nada, S., Nagai, K., Tarakhovsky, A., and Okada, M. (2000) Nature 404, 999-1003[CrossRef][Medline] [Order article via Infotrieve]
12. Brdicka, T., Pavlistova, D., Leo, A., Bruyns, E., Korinek, V., Angelisova, P., Scherer, J., Shevchenko, A., Hilgert, I., Cerny, J., Drbal, K., Kuramitsu, Y., Kornacker, B., Horejsi, V., and Schraven, B. (2000) J. Exp. Med. 191, 1591-1604[Abstract/Free Full Text]
13. Takeuchi, S., Takayama, Y., Ogawa, A., Tamura, K., and Okada, M. (2000) J. Biol. Chem. 275, 29183-29186[Abstract/Free Full Text]
14. Collaborative Computing Project 4. (1994) Acta Crystallogr. Sect. D Biol. Crystallogr. 50, 760-763[CrossRef][Medline] [Order article via Infotrieve]
15. Otwinowski, Z., and Minor, W. (1997) Methods Enzymol. 276, 307-326
16. Sheldrick, G. (1997) Methods Enzymol. 276, 628-641
17. de La Fortelle, E., and Bricogne, G. (1997) Methods Enzymol. 276, 472-494
18. Jones, T. A., Zou, J. Y., Cowan, S. W., and Kjeldgaard, M. (1991) Acta Crystallogr. Sect. A 47, 110-119
19. Brünger, A. T., Adams, P. D., Clore, G. M., DeLano, W. L., Gros, P., Grosse-Kunstleve, R. W., Jiang, J. S., Kuszewski, J., Nilges, M., Pannu, N. S., Read, R. J., Rice, L. M., Simonson, T., and Warren, G. L. (1998) Acta Crystallogr. Sect. D Biol. Crystallogr. 54, 905-921[CrossRef][Medline] [Order article via Infotrieve]
20. Okada, M., and Nakagawa, H. (1989) J. Biol. Chem. 264, 20886-20893[Abstract/Free Full Text]
21. Borchert, T. V., Mathieu, M., Zeelen, J. P., Courtneidge, S. A., and Wierenga, R. K. (1994) FEBS Lett. 341, 79-85[CrossRef][Medline] [Order article via Infotrieve]
22. Yamaguchi, H., and Hendrickson, W. A. (1996) Nature 384, 484-489[CrossRef][Medline] [Order article via Infotrieve]
23. Gonfloni, S., Weijland, A., Kretzschmar, J., and Superti-Furga, G. (2000) Nat. Struct. Biol. 7, 281-286[CrossRef][Medline] [Order article via Infotrieve]
24. Sun, G., Ramdas, L., Wang, W., Vinci, J., McMurray, J., and Budde, R. J. (2002) Arch Biochem. Biophys. 397, 11-17[CrossRef][Medline] [Order article via Infotrieve]
25. Sondhi, D., and Cole, P. A. (1999) Biochemistry 38, 11147-11155[CrossRef][Medline] [Order article via Infotrieve]
26. Sun, G., and Budde, R. J. (1999) Arch. Biochem. Biophys. 367, 167-172[CrossRef][Medline] [Order article via Infotrieve]
27. Lamers, M. B., Antson, A. A., Hubbard, R. E., Scott, R. K., and Williams, D. H. (1999) J. Mol. Biol. 285, 713-725[CrossRef][Medline] [Order article via Infotrieve]
28. Zhu, X., Kim, J. L., Newcomb, J. R., Rose, P. E., Stover, D. R., Toledo, L. M., Zao, H., and Morqenstern, K. A. (1999) Structure Fold Des. 7, 651-661[Medline] [Order article via Infotrieve]
29. Jeffrey, P. D., Russo, A. A., Polyak, K., Gibbs, E., Hurwitz, J., Massaque, J., and Pavletich, N. P. (1995) Nature 376, 313-320[CrossRef][Medline] [Order article via Infotrieve]
30. Young, M. A., Gonfloni, S., Superti-Furga, G., Roux, B., and Kuriyan, J. (2001) Cell 105, 115-126[CrossRef][Medline] [Order article via Infotrieve]


Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.


This article has been cited by other articles:


Home page
Biophys. JHome page
H. Fuss, W. Dubitzky, C. S. Downes, and M. J. Kurth
Src Family Kinases and Receptors: Analysis of Three Activation Mechanisms by Dynamic Systems Modeling
Biophys. J., March 15, 2008; 94(6): 1995 - 2006.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. A. Lieser, J. Shaffer, and J. A. Adams
Src Tail Phosphorylation Is Limited by Structural Changes in the Regulatory Tyrosine Kinase Csk
J. Biol. Chem., December 8, 2006; 281(49): 38004 - 38012.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
R. D. Meyer, X. Qian, H.-C. Guo, and N. Rahimi
Leucine Motif-dependent Tyrosine Autophosphorylation of Type III Receptor Tyrosine Kinases
J. Biol. Chem., March 31, 2006; 281(13): 8620 - 8627.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
N. Yokoyama, J. Lougheed, and W. T. Miller
Phosphorylation of WASP by the Cdc42-associated Kinase ACK1: DUAL HYDROXYAMINO ACID SPECIFICITY IN A TYROSINE KINASE
J. Biol. Chem., December 23, 2005; 280(51): 42219 - 42226.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. K. Ayrapetov, N. H. Nam, G. Ye, A. Kumar, K. Parang, and G. Sun
Functional Diversity of Csk, Chk, and Src SH2 Domains due to a Single Residue Variation
J. Biol. Chem., July 8, 2005; 280(27): 25780 - 25787.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. A. Lieser, C. Shindler, B. E. Aubol, S. Lee, G. Sun, and J. A. Adams
Phosphoryl Transfer Step in the C-terminal Src Kinase Controls Src Recognition
J. Biol. Chem., March 4, 2005; 280(9): 7769 - 7776.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. C. Lougheed, R.-H. Chen, P. Mak, and T. J. Stout
Crystal Structures of the Phosphorylated and Unphosphorylated Kinase Domains of the Cdc42-associated Tyrosine Kinase ACK1
J. Biol. Chem., October 15, 2004; 279(42): 44039 - 44045.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
S. Lee, X. Lin, N. H. Nam, K. Parang, and G. Sun
Determination of the substrate-docking site of protein tyrosine kinase C-terminal Src kinase
PNAS, December 9, 2003; 100(25): 14707 - 14712.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. Nada, T. Shima, H. Yanai, H. Husi, S. G. N. Grant, M. Okada, and T. Akiyama
Identification of PSD-93 as a Substrate for the Src Family Tyrosine Kinase Fyn
J. Biol. Chem., November 28, 2003; 278(48): 47610 - 47621.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
X. Lin, S. Lee, and G. Sun
Functions of the Activation Loop in Csk Protein-tyrosine Kinase
J. Biol. Chem., June 20, 2003; 278(26): 24072 - 24077.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. Stamos, M. X. Sliwkowski, and C. Eigenbrot
Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor
J. Biol. Chem., November 22, 2002; 277(48): 46265 - 46272.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
D. Wang, W. J. Esselman, and P. A. Cole
Substrate Conformational Restriction and CD45-catalyzed Dephosphorylation of Tail Tyrosine-phosphorylated Src Protein
J. Biol. Chem., October 18, 2002; 277(43): 40428 - 40433.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/17/14351    most recent
C200086200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ogawa, A.
Right arrow Articles by Tsukihara, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ogawa, A.
Right arrow Articles by Tsukihara, T.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.